Switch theme
Sign up to access all valuation multiples
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
1986
484
LTM Revenue $128M
LTM EBITDA $19.7M
$353M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lifecore Biomedical has a last 12-month revenue of $128M and a last 12-month EBITDA of $19.7M.
In the most recent fiscal year, Lifecore Biomedical achieved revenue of $128M and an EBITDA of $36.5M.
Lifecore Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lifecore Biomedical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $103M | $128M | XXX | XXX | XXX |
| Gross Profit | $50.4M | $28.0M | XXX | XXX | XXX |
| Gross Margin | 49% | 22% | XXX | XXX | XXX |
| EBITDA | -$33.0M | $36.5M | XXX | XXX | XXX |
| EBITDA Margin | -32% | 28% | XXX | XXX | XXX |
| Net Profit | -$97.4M | -$99.6M | XXX | XXX | XXX |
| Net Margin | -94% | -78% | XXX | XXX | XXX |
| Net Debt | $137M | $82.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lifecore Biomedical's stock price is $6.
Lifecore Biomedical has current market cap of $228M, and EV of $353M.
See Lifecore Biomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $353M | $228M | XXX | XXX | XXX | XXX | $-1.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lifecore Biomedical has market cap of $228M and EV of $353M.
Lifecore Biomedical's trades at 2.8x LTM EV/Revenue multiple, and 18.0x LTM EBITDA.
Analysts estimate Lifecore Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lifecore Biomedical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $353M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 13.3x | XXX | XXX | XXX |
| P/E | -10.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLifecore Biomedical's NTM/LTM revenue growth is 3%
Lifecore Biomedical's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Lifecore Biomedical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lifecore Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lifecore Biomedical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -211% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 24% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 38% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lifecore Biomedical acquired XXX companies to date.
Last acquisition by Lifecore Biomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Lifecore Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lifecore Biomedical founded? | Lifecore Biomedical was founded in 1986. |
| Where is Lifecore Biomedical headquartered? | Lifecore Biomedical is headquartered in United States of America. |
| How many employees does Lifecore Biomedical have? | As of today, Lifecore Biomedical has 484 employees. |
| Who is the CEO of Lifecore Biomedical? | Lifecore Biomedical's CEO is Mr. Paul Josephs. |
| Is Lifecore Biomedical publicy listed? | Yes, Lifecore Biomedical is a public company listed on NAS. |
| What is the stock symbol of Lifecore Biomedical? | Lifecore Biomedical trades under LFCR ticker. |
| When did Lifecore Biomedical go public? | Lifecore Biomedical went public in 1996. |
| Who are competitors of Lifecore Biomedical? | Similar companies to Lifecore Biomedical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Lifecore Biomedical? | Lifecore Biomedical's current market cap is $228M |
| What is the current revenue of Lifecore Biomedical? | Lifecore Biomedical's last 12-month revenue is $128M. |
| What is the current EBITDA of Lifecore Biomedical? | Lifecore Biomedical's last 12-month EBITDA is $19.7M. |
| What is the current EV/Revenue multiple of Lifecore Biomedical? | Current revenue multiple of Lifecore Biomedical is 2.8x. |
| What is the current EV/EBITDA multiple of Lifecore Biomedical? | Current EBITDA multiple of Lifecore Biomedical is 18.0x. |
| What is the current revenue growth of Lifecore Biomedical? | Lifecore Biomedical revenue growth between 2023 and 2024 was 24%. |
| Is Lifecore Biomedical profitable? | Yes, Lifecore Biomedical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
